The most high-profile departure will be the biotech’s chief medical officer Maria Koehler, M.D., Ph.D. Story Feb. 14 - Spotlight Therapeutics: The San Francisco gene editor has closed its doors.

Because biotech involves expensive R&D and clinical testing, it is susceptible to shifting rate patterns. According to Genetic Engineering and Biotechnology News, lower rates increase the amount ...

A new year means a new Fierce Biotech Fundraising Tracker to record the significant amounts of venture capital being funneled into the industry. We're maintaining the criteria we used for last ...

Chess prodigy D Gukesh made headlines by showcasing his dance skills at Vidit Gujrathi's wedding to Nidhi Kataria, attended by chess luminaries including Viswanathan Anand. The marriage took place ...

Many of the issues they address directly affect small-cap and penny stocks, allowing more room for startups to perform speculative R&D and retain the fruits of their study. The history of biotech ...

Biotech stocks are in the eye of the storm as the world recovers from the global pandemic. Government institutions and professional traders are banking on biotech stocks to continually develop a ...

An Indigenous and family-owned agricultural biotech company based in Alberta has announced it has secured $2 million in seed money from an Indigenous-led investment firm. AdvancedAG, which is ...

First, let’s take a look at the private biotech investments in March 2025, breaking them down by value ... The investment from this will help the company to accelerate its frontier artificial ...

Biotech companies create drugs from living organisms, requiring a BLA for FDA approval. Pharma companies develop drugs from chemicals, needing an NDA for FDA approval. Many firms blend biotech and ...